JP2009544680A - ポリサッカライドによるタンパク質のｎ末端誘導体化 - Google Patents

ポリサッカライドによるタンパク質のｎ末端誘導体化 Download PDF

Info

Publication number
JP2009544680A
JP2009544680A JP2009521342A JP2009521342A JP2009544680A JP 2009544680 A JP2009544680 A JP 2009544680A JP 2009521342 A JP2009521342 A JP 2009521342A JP 2009521342 A JP2009521342 A JP 2009521342A JP 2009544680 A JP2009544680 A JP 2009544680A
Authority
JP
Japan
Prior art keywords
protein
sialic acid
polysaccharide
buffer
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009521342A
Other languages
English (en)
Japanese (ja)
Inventor
サンジャイ ジェイン
ピーター レイン
グレゴリー グレゴリアディス
Original Assignee
リポクセン テクノロジーズ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リポクセン テクノロジーズ リミテッド filed Critical リポクセン テクノロジーズ リミテッド
Publication of JP2009544680A publication Critical patent/JP2009544680A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C12Y301/21001—Deoxyribonuclease I (3.1.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
JP2009521342A 2006-07-25 2007-07-25 ポリサッカライドによるタンパク質のｎ末端誘導体化 Pending JP2009544680A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06117830 2006-07-25
PCT/GB2007/002839 WO2008012540A1 (en) 2006-07-25 2007-07-25 N-terminal polysialylation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013022825A Division JP5420091B2 (ja) 2006-07-25 2013-02-08 ポリサッカライドによるタンパク質のｎ末端誘導体化

Publications (1)

Publication Number Publication Date
JP2009544680A true JP2009544680A (ja) 2009-12-17

Family

ID=37397314

Family Applications (14)

Application Number Title Priority Date Filing Date
JP2009521343A Pending JP2009544681A (ja) 2006-07-25 2007-07-25 エリスロポエチンの多糖誘導体
JP2009521336A Expired - Fee Related JP5419689B2 (ja) 2006-07-25 2007-07-25 顆粒球コロニー刺激因子の誘導体化
JP2009521337A Expired - Fee Related JP5096466B2 (ja) 2006-07-25 2007-07-25 Ｎ末端ポリシアリル化
JP2009521342A Pending JP2009544680A (ja) 2006-07-25 2007-07-25 ポリサッカライドによるタンパク質のｎ末端誘導体化
JP2012205475A Expired - Fee Related JP5586669B2 (ja) 2006-07-25 2012-09-19 Ｎ末端ポリシアリル化
JP2012287324A Active JP5542195B2 (ja) 2006-07-25 2012-12-28 エリスロポエチンの多糖誘導体
JP2013022825A Expired - Fee Related JP5420091B2 (ja) 2006-07-25 2013-02-08 ポリサッカライドによるタンパク質のｎ末端誘導体化
JP2013160269A Active JP5941440B2 (ja) 2006-07-25 2013-08-01 ポリサッカライドによるタンパク質のｎ末端誘導体化
JP2014025061A Active JP6165079B2 (ja) 2006-07-25 2014-02-13 エリスロポエチンの多糖誘導体
JP2014154037A Expired - Fee Related JP5912152B2 (ja) 2006-07-25 2014-07-29 Ｎ末端ポリシアリル化
JP2015075148A Expired - Fee Related JP6055506B2 (ja) 2006-07-25 2015-04-01 ポリサッカライドによるタンパク質のｎ末端誘導体化
JP2016020557A Expired - Fee Related JP6243456B2 (ja) 2006-07-25 2016-02-05 ポリサッカライドによるタンパク質のｎ末端誘導体化
JP2016149090A Expired - Fee Related JP6203342B2 (ja) 2006-07-25 2016-07-29 エリスロポエチンの多糖誘導体
JP2017157728A Expired - Fee Related JP6581157B2 (ja) 2006-07-25 2017-08-18 エリスロポエチンの多糖誘導体

Family Applications Before (3)

Application Number Title Priority Date Filing Date
JP2009521343A Pending JP2009544681A (ja) 2006-07-25 2007-07-25 エリスロポエチンの多糖誘導体
JP2009521336A Expired - Fee Related JP5419689B2 (ja) 2006-07-25 2007-07-25 顆粒球コロニー刺激因子の誘導体化
JP2009521337A Expired - Fee Related JP5096466B2 (ja) 2006-07-25 2007-07-25 Ｎ末端ポリシアリル化

Family Applications After (10)

Application Number Title Priority Date Filing Date
JP2012205475A Expired - Fee Related JP5586669B2 (ja) 2006-07-25 2012-09-19 Ｎ末端ポリシアリル化
JP2012287324A Active JP5542195B2 (ja) 2006-07-25 2012-12-28 エリスロポエチンの多糖誘導体
JP2013022825A Expired - Fee Related JP5420091B2 (ja) 2006-07-25 2013-02-08 ポリサッカライドによるタンパク質のｎ末端誘導体化
JP2013160269A Active JP5941440B2 (ja) 2006-07-25 2013-08-01 ポリサッカライドによるタンパク質のｎ末端誘導体化
JP2014025061A Active JP6165079B2 (ja) 2006-07-25 2014-02-13 エリスロポエチンの多糖誘導体
JP2014154037A Expired - Fee Related JP5912152B2 (ja) 2006-07-25 2014-07-29 Ｎ末端ポリシアリル化
JP2015075148A Expired - Fee Related JP6055506B2 (ja) 2006-07-25 2015-04-01 ポリサッカライドによるタンパク質のｎ末端誘導体化
JP2016020557A Expired - Fee Related JP6243456B2 (ja) 2006-07-25 2016-02-05 ポリサッカライドによるタンパク質のｎ末端誘導体化
JP2016149090A Expired - Fee Related JP6203342B2 (ja) 2006-07-25 2016-07-29 エリスロポエチンの多糖誘導体
JP2017157728A Expired - Fee Related JP6581157B2 (ja) 2006-07-25 2017-08-18 エリスロポエチンの多糖誘導体

Country Status (10)

Country Link
US (22) US10300144B2 (enExample)
EP (6) EP2041167B1 (enExample)
JP (14) JP2009544681A (enExample)
KR (1) KR101400105B1 (enExample)
CN (2) CN101511391B (enExample)
AT (1) ATE467642T1 (enExample)
DE (1) DE602007006492D1 (enExample)
ES (5) ES2647528T3 (enExample)
RU (1) RU2432175C2 (enExample)
WO (4) WO2008012540A1 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005016974A1 (en) * 2003-08-12 2005-02-24 Lipoxen Technologies Limited Sialic acid derivatives for protein derivatisation and conjugation
ES2294535T3 (es) 2003-08-12 2008-04-01 Lipoxen Technologies Limited Derivados del acido polisialico.
KR101400105B1 (ko) 2006-07-25 2014-06-19 리폭센 테크놀로지즈 리미티드 Ｎ-말단 폴리시알화
BRPI0720282B8 (pt) 2006-12-15 2021-05-25 Baxalta GmbH construção proteica, composição farmacêutica, e, kit
DK2115010T3 (da) 2007-02-28 2012-02-06 Lipoxen Technologies Ltd Mindskelse af endotoksin i polysialinsyrer
US8742079B2 (en) 2007-08-20 2014-06-03 Protalix Ltd. Saccharide-containing protein conjugates and uses thereof
RU2391354C1 (ru) * 2008-10-15 2010-06-10 Учреждение Российской академии наук Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова РАН, Российская Федерация, от имени которой выступает Федеральное агентство по науке и инновациям Комплекс биологически активного рекомбинантного белка с полисиаловой кислотой
MX2011004195A (es) * 2008-10-20 2011-09-27 Usv Ltd Un proceso mejorado para la pegilacion de proteinas.
WO2010051335A1 (en) * 2008-10-31 2010-05-06 Amgen Inc. Materials and methods relating to stem cell mobilization by multi-pegylated granulocyte colony stimulating factor
US8846103B2 (en) 2009-01-28 2014-09-30 Smartcells, Inc. Exogenously triggered controlled release materials and uses thereof
MX2011007930A (es) 2009-01-28 2011-09-06 Smartcells Inc Conjugados de insulina cristalina.
AU2010208305A1 (en) 2009-01-28 2011-09-08 Smartcells, Inc. Synthetic conjugates and uses thereof
BRPI1007457A2 (pt) 2009-01-28 2015-08-25 Smartcells Inc Conjungado, formulação de liberação prolongada, e, sistema de distribuição de bomba.
JP2012520879A (ja) 2009-03-20 2012-09-10 スマートセルズ・インコーポレイテツド 末端官能基化コンジュゲートおよびその用途
WO2010107520A1 (en) 2009-03-20 2010-09-23 Smartcells, Inc. Soluble non-depot insulin conjugates and uses thereof
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
HRP20160916T1 (hr) 2009-07-27 2016-11-18 Baxalta GmbH Konjugati proteina za koagulaciju krvi
US9795683B2 (en) * 2009-07-27 2017-10-24 Lipoxen Technologies Limited Glycopolysialylation of non-blood coagulation proteins
CN104530182A (zh) * 2009-07-27 2015-04-22 利普森技术有限公司 非凝血蛋白的糖基多唾液酸化
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US9194011B2 (en) 2009-11-17 2015-11-24 Protalix Ltd. Stabilized alpha-galactosidase and uses thereof
CN101787117B (zh) * 2010-02-08 2012-05-23 江南大学 聚乙二醇-聚唾液酸嵌段共聚物的制备方法及应用
MX2012013375A (es) * 2010-05-17 2013-04-11 Cebix Inc Peptido c pegilado.
WO2011156242A2 (en) * 2010-06-11 2011-12-15 Lpath, Inc. Improved anti-lysophospholipid antibody design using antibody structures
EP2598527A4 (en) 2010-07-28 2014-01-08 Smartcells Inc RECOMBINANT EXPRESSED INSULIN POLYPEPTIDES AND APPLICATIONS THEREOF
US8933207B2 (en) 2010-07-28 2015-01-13 Smartcells, Inc. Drug-ligand conjugates, synthesis thereof, and intermediates thereto
JP2013541500A (ja) 2010-07-28 2013-11-14 スマートセルズ・インコーポレイテツド 組換えレクチン、結合部位修飾レクチンおよびそれらの用途
AU2011356137A1 (en) 2011-01-20 2013-08-15 Protalix Ltd. Nucleic acid construct for expression of alpha-galactosidase in plants and plant cells
EP2780030A4 (en) 2011-11-17 2015-11-18 Cebix Ab PEGYLATED C-PEPTIDE
RU2676307C2 (ru) 2013-10-04 2018-12-27 Мерк Шарп И Доум Корп. Чувствительные к глюкозе конъюгаты инсулина
WO2015130963A2 (en) 2014-02-27 2015-09-03 Xenetic Biosciences, Inc. Compositions and methods for administering insulin or insulin-like protein to the brain
JP2019218265A (ja) * 2016-09-14 2019-12-26 生化学工業株式会社 ペプチドの血中滞留性を増強させる方法
US20200179524A1 (en) * 2017-04-25 2020-06-11 Lipoxen Technologies Limited Methods of treating multiple myeloma cancers expressing high levels of epo-receptor using psa-epo
WO2018197547A1 (en) 2017-04-25 2018-11-01 Lipoxen Technologies Limited Methods of treating diseases related to net formation with parenteral administration of polysialylated dnase i
WO2020099513A1 (en) * 2018-11-13 2020-05-22 Lipoxen Technologies Limited Glycopolysialylation of blinatumomab
KR20210151780A (ko) * 2019-02-04 2021-12-14 제네틱 바이오사이언시스, 인코포레이티드 글리코폴리시알화된 치료 단백질 사용 방법
MX2022000285A (es) 2019-07-08 2022-02-03 Gi Innovation Inc Dimero de polipeptido con alto contenido de acido sialico, que comprende el dominio extracelular de la subunidad alfa del receptor fc de ige y composicion farmaceutica que comprende el mismo.
WO2022033480A1 (zh) * 2020-08-11 2022-02-17 隆延生物科技（上海）有限公司 一种液体制剂及其应用
CN114966021B (zh) * 2022-05-19 2025-03-04 山东博科生物产业有限公司 一种稳定的脂蛋白相关磷脂酶a2测定试剂盒

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0733793A (ja) * 1993-07-23 1995-02-03 Snow Brand Milk Prod Co Ltd シアル酸粉末
JPH09506116A (ja) * 1994-10-12 1997-06-17 アムジエン・インコーポレーテツド Ｎ末端化学修飾タンパク質組成物および方法
JP2003533537A (ja) * 2000-05-16 2003-11-11 リポクセン テクノロジーズ リミテッド タンパク質の誘導体化
WO2005016973A1 (en) * 2003-08-12 2005-02-24 Lipoxen Technologies Limited Polysialic acid derivatives
WO2005016974A1 (en) * 2003-08-12 2005-02-24 Lipoxen Technologies Limited Sialic acid derivatives for protein derivatisation and conjugation
WO2006016168A2 (en) * 2004-08-12 2006-02-16 Lipoxen Technologies Limited Sialic acid derivatives

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
DE2930542A1 (de) 1979-07-27 1981-02-12 Hoechst Ag Neue insulinderivate und verfahren zu ihrer herstellung
US5308617A (en) * 1988-08-10 1994-05-03 Halzyme Ltd. Protein heparin conjugates
US7217689B1 (en) * 1989-10-13 2007-05-15 Amgen Inc. Glycosylation analogs of erythropoietin
AU646822B2 (en) * 1989-10-13 1994-03-10 Kirin-Amgen Inc. Erythropoietin isoforms
US5846951A (en) 1991-06-06 1998-12-08 The School Of Pharmacy, University Of London Pharmaceutical compositions
GB9112212D0 (en) 1991-06-06 1991-07-24 Gregoriadis Gregory Pharmaceutical compositions
ES2115638T3 (es) 1991-12-30 1998-07-01 Akzo Nobel Nv Composicion tiroactiva de liberacion controlada.
US20030053982A1 (en) * 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
CA2299548C (en) * 1997-08-05 2009-12-29 Bioniche Inc. Composition and method for regulating cell proliferation and cell death
AU2794199A (en) 1998-02-26 1999-09-15 Robertas Bunevicius Thyroid hormone replacement using sustained release triiodothyronine
RU2141531C1 (ru) 1999-05-26 1999-11-20 Российское акционерное общество открытого типа "Биопрепарат" Способ получения рекомбинантного инсулина человека
US6323311B1 (en) * 1999-09-22 2001-11-27 University Of Utah Research Foundation Synthesis of insulin derivatives
DE60116758T2 (de) 2000-05-18 2006-11-02 Therics, Inc. Einkapselung eines toxischen kerns in einen nicht-toxischen bereich in einer oralen darreichungsform
US7118737B2 (en) * 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
DE60137525D1 (de) * 2000-10-16 2009-03-12 Chugai Pharmaceutical Co Ltd Peg-modifiziertes erythropoietin
JP4656814B2 (ja) 2000-12-20 2011-03-23 エフ．ホフマン−ラ ロシュ アーゲー エリスロポエチンコンジュゲート
KR100401296B1 (ko) 2000-12-27 2003-10-11 드림바이오젠 주식회사 수식물질에 의해 수식된 단백질 변이체 및 이것의 제조방법
ES2411007T3 (es) 2001-10-10 2013-07-04 Novo Nordisk A/S Remodelación y glicoconjugación de péptidos
US7125843B2 (en) * 2001-10-19 2006-10-24 Neose Technologies, Inc. Glycoconjugates including more than one peptide
WO2003055526A2 (en) 2001-12-21 2003-07-10 Maxygen Aps Erythropoietin conjugates
ITPD20010302A1 (it) 2001-12-28 2003-06-28 Bbs Riva Spa Dispositivo idraulico per pompare e / p intercettare metallo allo stato fuso
US6763226B1 (en) 2002-07-31 2004-07-13 Computer Science Central, Inc. Multifunctional world wide walkie talkie, a tri-frequency cellular-satellite wireless instant messenger computer and network for establishing global wireless volp quality of service (qos) communications, unified messaging, and video conferencing via the internet
EP1681303B1 (en) * 2002-09-11 2013-09-04 Fresenius Kabi Deutschland GmbH HASylated polypeptides, especially HASylated erythropoietin
KR101045401B1 (ko) * 2002-09-11 2011-06-30 프레제니우스 카비 도이치란트 게엠베하 하이드록시알킬 전분 유도체
EP1400533A1 (en) * 2002-09-11 2004-03-24 Fresenius Kabi Deutschland GmbH HASylated polypeptides, especially HASylated erythropoietin
CN1777440A (zh) 2003-04-11 2006-05-24 Pr药品有限公司 位点特异性蛋白质偶联物的制备方法
WO2004101619A1 (ja) 2003-05-15 2004-11-25 Shionogi Co., Ltd. 機能的糖ペプチドの合理的設計および合成
US7074755B2 (en) 2003-05-17 2006-07-11 Centocor, Inc. Erythropoietin conjugate compounds with extended half-lives
WO2005003149A1 (en) 2003-07-03 2005-01-13 Cipla Limited Process for the preparation of finasteride form i
CA2534652C (en) 2003-08-05 2013-12-10 Dematic Corp. Motorized roller transverse drive
CA2948114C (en) 2003-08-06 2019-02-26 Che-Hung Robert Lee Polysaccharide-protein conjugate vaccines
MXPA06001358A (es) 2003-08-08 2006-05-15 Fresenius Kabi Gmbh Conjugados de hidroxialquil almidon y g-csf.
KR20060120141A (ko) * 2003-11-24 2006-11-24 네오스 테크놀로지스, 인크. 글리코페질화 에리트로포이에틴
US7956032B2 (en) * 2003-12-03 2011-06-07 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
AU2004296855B2 (en) 2003-12-03 2011-01-06 Ratiopharm Gmbh Glycopegylated Granulocyte Colony Stimulating Factor
CN101659704A (zh) * 2004-03-11 2010-03-03 弗雷泽纽斯卡比德国有限公司 通过还原氨基化制备的羟烷基淀粉和蛋白质的偶联物
FR2868071B1 (fr) * 2004-03-26 2006-06-09 Biomerieux Sa Reactifs de marquage, procedes de synthese de tels reactifs et procedes de detection de molecules biologiques
DE102004030392A1 (de) 2004-06-23 2006-01-19 Endress + Hauser Flowtec Ag, Reinach Meßwandler vom Vibrationstyp
WO2006014148A2 (fr) 2004-08-04 2006-02-09 Sergey Alexandrovich Orlov Procede permettant d'organiser un processus de jeu a action intermittente
GB2416993A (en) 2004-08-11 2006-02-15 Dinesh Verma Opthalmic prosthesis
US8652334B2 (en) 2004-08-12 2014-02-18 Lipoxen Technologies Limited Fractionation of charged polysaccharide
WO2006074467A2 (en) 2005-01-10 2006-07-13 Neose Technologies, Inc. Glycopegylated granulocyte colony stimulating factor
TWI376234B (en) * 2005-02-01 2012-11-11 Msd Oss Bv Conjugates of a polypeptide and an oligosaccharide
US8217154B2 (en) 2005-02-23 2012-07-10 Lipoxen Technologies Limited Activated sialic acid derivatives for protein derivatisation and conjugation
JP3989936B2 (ja) * 2005-04-07 2007-10-10 進 須永 抗腫瘍剤及び新規ｄｎアーゼ
US20070099820A1 (en) 2005-10-19 2007-05-03 Smartcells, Inc. Polymer-drug conjugates
KR101400105B1 (ko) * 2006-07-25 2014-06-19 리폭센 테크놀로지즈 리미티드 Ｎ-말단 폴리시알화
CN102470144A (zh) 2009-07-16 2012-05-23 花王株式会社 进食后血中胰岛素浓度上升抑制剂
US9006400B2 (en) 2011-09-26 2015-04-14 Novartis Ag Fibroblast growth factor-21-Fc fusion proteins

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0733793A (ja) * 1993-07-23 1995-02-03 Snow Brand Milk Prod Co Ltd シアル酸粉末
JPH09506116A (ja) * 1994-10-12 1997-06-17 アムジエン・インコーポレーテツド Ｎ末端化学修飾タンパク質組成物および方法
JP2003533537A (ja) * 2000-05-16 2003-11-11 リポクセン テクノロジーズ リミテッド タンパク質の誘導体化
WO2005016973A1 (en) * 2003-08-12 2005-02-24 Lipoxen Technologies Limited Polysialic acid derivatives
WO2005016974A1 (en) * 2003-08-12 2005-02-24 Lipoxen Technologies Limited Sialic acid derivatives for protein derivatisation and conjugation
JP2007501889A (ja) * 2003-08-12 2007-02-01 リポクセン テクノロジーズ リミテッド タンパク質の誘導体化及び結合のためのシアル酸誘導体
WO2006016168A2 (en) * 2004-08-12 2006-02-16 Lipoxen Technologies Limited Sialic acid derivatives

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6011051325; Ｂｉｏｃｈｉｍ．　Ｂｉｏｐｈｙｓ．　Ａｃｔａ． ｖｏｌ．１６２２, 2003, ｐ．４２-９ *
JPN6011051329; Ｉｎｔ．　Ｊ．　Ｐｈａｒｍ． ｖｏｌ．３００, 2005, ｐ．１２５-３０ *

Also Published As

Publication number Publication date
US9492557B2 (en) 2016-11-15
EP2041167A1 (en) 2009-04-01
US20180289823A1 (en) 2018-10-11
EP2043616B1 (en) 2016-01-27
ES2581902T3 (es) 2016-09-08
EP3299033A1 (en) 2018-03-28
US20220133898A1 (en) 2022-05-05
DE602007006492D1 (de) 2010-06-24
US20140161765A1 (en) 2014-06-12
US20100022443A1 (en) 2010-01-28
US20190216938A1 (en) 2019-07-18
US8394921B2 (en) 2013-03-12
US20140134147A1 (en) 2014-05-15
JP5941440B2 (ja) 2016-06-29
JP5912152B2 (ja) 2016-04-27
JP6165079B2 (ja) 2017-07-19
EP2043616A1 (en) 2009-04-08
RU2009105696A (ru) 2010-08-27
US9234020B2 (en) 2016-01-12
JP5420091B2 (ja) 2014-02-19
WO2008012540A9 (en) 2009-03-12
ES2647528T3 (es) 2017-12-22
WO2008012542A8 (en) 2009-07-16
CN103169984B (zh) 2016-08-03
JP5096466B2 (ja) 2012-12-12
EP2043693B1 (en) 2016-04-27
US20170080054A1 (en) 2017-03-23
US8299026B2 (en) 2012-10-30
CN103169984A (zh) 2013-06-26
JP2015145400A (ja) 2015-08-13
US9579393B2 (en) 2017-02-28
JP2009544677A (ja) 2009-12-17
JP5542195B2 (ja) 2014-07-09
US20150252090A1 (en) 2015-09-10
JP2018039791A (ja) 2018-03-15
US20160095930A1 (en) 2016-04-07
JP2013049675A (ja) 2013-03-14
WO2008012525A1 (en) 2008-01-31
US20150158924A1 (en) 2015-06-11
WO2008012540A1 (en) 2008-01-31
US20140315802A1 (en) 2014-10-23
US9040478B2 (en) 2015-05-26
JP2009544678A (ja) 2009-12-17
US20100056427A1 (en) 2010-03-04
ATE467642T1 (de) 2010-05-15
US20100022441A1 (en) 2010-01-28
US20130116176A1 (en) 2013-05-09
US8933026B2 (en) 2015-01-13
CN101511391A (zh) 2009-08-19
EP2630972A2 (en) 2013-08-28
US8981050B2 (en) 2015-03-17
US9549990B2 (en) 2017-01-24
JP5586669B2 (ja) 2014-09-10
US9474805B2 (en) 2016-10-25
ES2581983T3 (es) 2016-09-08
US8946406B2 (en) 2015-02-03
US9492556B2 (en) 2016-11-15
WO2008012542A3 (en) 2008-05-15
JP2014114315A (ja) 2014-06-26
WO2008012528A1 (en) 2008-01-31
US9789163B2 (en) 2017-10-17
EP2043693A1 (en) 2009-04-08
JP6055506B2 (ja) 2016-12-27
JP6243456B2 (ja) 2017-12-06
US8299015B2 (en) 2012-10-30
EP2630972A3 (en) 2013-10-16
JP2017018107A (ja) 2017-01-26
JP5419689B2 (ja) 2014-02-19
JP6203342B2 (ja) 2017-09-27
JP6581157B2 (ja) 2019-09-25
RU2432175C2 (ru) 2011-10-27
US20140309166A1 (en) 2014-10-16
JP2016128493A (ja) 2016-07-14
JP2013100309A (ja) 2013-05-23
ES2344670T3 (es) 2010-09-02
US10300144B2 (en) 2019-05-28
JP2013121982A (ja) 2013-06-20
US20160129123A1 (en) 2016-05-12
US9266936B2 (en) 2016-02-23
WO2008012525A8 (en) 2010-04-29
US20170058273A1 (en) 2017-03-02
US20170119893A1 (en) 2017-05-04
KR101400105B1 (ko) 2014-06-19
US20100016217A1 (en) 2010-01-21
US20150147307A1 (en) 2015-05-28
US8796207B2 (en) 2014-08-05
CN101511391B (zh) 2013-03-13
ES2569066T3 (es) 2016-05-06
JP2015007062A (ja) 2015-01-15
WO2008012542A2 (en) 2008-01-31
US20140309407A1 (en) 2014-10-16
US20160129124A1 (en) 2016-05-12
EP2043692B1 (en) 2016-05-18
KR20090057370A (ko) 2009-06-05
EP2043692A2 (en) 2009-04-08
JP2009544681A (ja) 2009-12-17
EP2041167B1 (en) 2010-05-12
JP2013241446A (ja) 2013-12-05
EP2630972B1 (en) 2017-08-30

Similar Documents

Publication Publication Date Title
JP6243456B2 (ja) ポリサッカライドによるタンパク質のｎ末端誘導体化
Class et al. Patent application title: N-Terminal Derivatisation of Proteins With Polysaccharides Inventors: Sanjay Jain (London, GB) Peter Laing (London, GB) Gregory Gregoriadis (London, GB) Assignees: Lipoxen Technologies Limited
Class et al. Patent application title: N-terminal Derivatisation of Proteins with Polysaccharides
Class et al. Patent application title: Derivatisation of Erythropoietin (EPO) Inventors: Sanjay Jain (London, GB) Peter Laing (London, GB) Gregory Gregoriadis (London, GB) Norbert Oskar Rumpf (London, GB) Norbert Oskar Rumpf (London, GB) Assignees: Lipoxen Technologies Limited
Class et al. Patent application title: DERIVATISATION OF GRANULOCYTE COLONY-STIMULATING FACTOR Inventors: Sanjay Jain (London, GB) Peter Laing (London, GB) Gregory Gregoriadis (London, GB) Assignees: Lipoxen Technologies Limited

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111004

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111222

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120911

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121206

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121213

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130528